Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
Identifieur interne : 002A73 ( Main/Exploration ); précédent : 002A72; suivant : 002A74Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
Auteurs : Melvin D. Yahr [États-Unis] ; Marina R. Mendoza [États-Unis] ; Daniel Moros [États-Unis] ; Kenneth J. Bergmann [États-Unis]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1983-07.
English descriptors
- KwdEn :
Abstract
ABSTRACT — There are at present numerous pharmacological agents available for the control of parkinson symptoms. None are ideal; all have their limitations. The most potent is levodopa administered with a peripheral decarboxylase inhibitor. However, because its effectiveness declines after long‐term use and side effects increase in severity, it should be reserved for individuals with established symptoms which are functionally impairing. In patients with minimal symptoms, anticholinergic agents, or agents which facilitate dopaminergic mechanisms normally operative in the nervous system, should be used. In a limited trial, deprenyl has produced promising results during this phase of parkinsonism. Deprenyl's major usefulness however, has been demonstrated in patients under treatment with levodopa which has become complicated by fluctuating responses – particularly those of the end‐start‐dose variety. In such patients, it is possible to achieve an increase in “on” time and a decrease in the severity of parkinsonism. In most patients, such a response can maintained for a period of two years or longer.
Url:
DOI: 10.1111/j.1600-0404.1983.tb01521.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)</title><author><name sortKey="Yahr, Melvin D" sort="Yahr, Melvin D" uniqKey="Yahr M" first="Melvin D." last="Yahr">Melvin D. Yahr</name></author><author><name sortKey="Mendoza, Marina R" sort="Mendoza, Marina R" uniqKey="Mendoza M" first="Marina R." last="Mendoza">Marina R. Mendoza</name></author><author><name sortKey="Moros, Daniel" sort="Moros, Daniel" uniqKey="Moros D" first="Daniel" last="Moros">Daniel Moros</name></author><author><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:24812BEFA4A8EA12C813CD155094ACF9E2B398CB</idno><date when="1983" year="1983">1983</date><idno type="doi">10.1111/j.1600-0404.1983.tb01521.x</idno><idno type="url">https://api.istex.fr/document/24812BEFA4A8EA12C813CD155094ACF9E2B398CB/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A08</idno><idno type="wicri:Area/Main/Curation">001753</idno><idno type="wicri:Area/Main/Exploration">002A73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)</title><author><name sortKey="Yahr, Melvin D" sort="Yahr, Melvin D" uniqKey="Yahr M" first="Melvin D." last="Yahr">Melvin D. Yahr</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Center for Research in Parkinson's and Allied Diseases, Mt. Sinai School of Medicine, City University of New York and the Mt. Sinai Hospital, New York, N.Y.</wicri:regionArea><wicri:noRegion>N.Y.</wicri:noRegion></affiliation></author><author><name sortKey="Mendoza, Marina R" sort="Mendoza, Marina R" uniqKey="Mendoza M" first="Marina R." last="Mendoza">Marina R. Mendoza</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Center for Research in Parkinson's and Allied Diseases, Mt. Sinai School of Medicine, City University of New York and the Mt. Sinai Hospital, New York, N.Y.</wicri:regionArea><wicri:noRegion>N.Y.</wicri:noRegion></affiliation></author><author><name sortKey="Moros, Daniel" sort="Moros, Daniel" uniqKey="Moros D" first="Daniel" last="Moros">Daniel Moros</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Center for Research in Parkinson's and Allied Diseases, Mt. Sinai School of Medicine, City University of New York and the Mt. Sinai Hospital, New York, N.Y.</wicri:regionArea><wicri:noRegion>N.Y.</wicri:noRegion></affiliation></author><author><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Center for Research in Parkinson's and Allied Diseases, Mt. Sinai School of Medicine, City University of New York and the Mt. Sinai Hospital, New York, N.Y.</wicri:regionArea><wicri:noRegion>N.Y.</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1983-07">1983-07</date><biblScope unit="volume">68</biblScope><biblScope unit="supplement">s95</biblScope><biblScope unit="page" from="95">95</biblScope><biblScope unit="page" to="102">102</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">24812BEFA4A8EA12C813CD155094ACF9E2B398CB</idno><idno type="DOI">10.1111/j.1600-0404.1983.tb01521.x</idno><idno type="ArticleID">ANE95</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>deprenyl (selegiline) indication</term><term>mechanisms and means of control</term><term>plan of treatment in various phases</term><term>use of cholinergic and dopaminergic agents</term><term>“on‐off” phenomena types</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABSTRACT — There are at present numerous pharmacological agents available for the control of parkinson symptoms. None are ideal; all have their limitations. The most potent is levodopa administered with a peripheral decarboxylase inhibitor. However, because its effectiveness declines after long‐term use and side effects increase in severity, it should be reserved for individuals with established symptoms which are functionally impairing. In patients with minimal symptoms, anticholinergic agents, or agents which facilitate dopaminergic mechanisms normally operative in the nervous system, should be used. In a limited trial, deprenyl has produced promising results during this phase of parkinsonism. Deprenyl's major usefulness however, has been demonstrated in patients under treatment with levodopa which has become complicated by fluctuating responses – particularly those of the end‐start‐dose variety. In such patients, it is possible to achieve an increase in “on” time and a decrease in the severity of parkinsonism. In most patients, such a response can maintained for a period of two years or longer.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Yahr, Melvin D" sort="Yahr, Melvin D" uniqKey="Yahr M" first="Melvin D." last="Yahr">Melvin D. Yahr</name></noRegion><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><name sortKey="Mendoza, Marina R" sort="Mendoza, Marina R" uniqKey="Mendoza M" first="Marina R." last="Mendoza">Marina R. Mendoza</name><name sortKey="Moros, Daniel" sort="Moros, Daniel" uniqKey="Moros D" first="Daniel" last="Moros">Daniel Moros</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:24812BEFA4A8EA12C813CD155094ACF9E2B398CB
|texte= Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
}}
| This area was generated with Dilib version V0.6.23. |  |